He, K. Abdelraouf, K. R. Ledesma, D. S. L. Chow, V. H. Tam; Univ. of Houston, Houston, TX. J. Kubin Komp Lindgren N. Kristoffersson, J. Nyberg, L. E. Friberg; Uppsala Univ., Uppsala, Sweden. Bouchene

39 SUNDAY SCIENTIFIC SESSIONS Final Program A-016 Comparison of Methods for Doripenem D Population Pharmacodynamic PPD Analysis Optimization of Dosing Regimens Using Monte Carlo Simulation MCS

N. S. Ly, G. G. Rao, R. L. Soon, L. Wollenberg, K. Yang, B. T. Tsuji, A. Forrest; SUNY, Buffalo, NY.

A-017 Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients

M. B. Kays

1 , S. C. Cheatham 2 , M. R. Fleming 3 , J. M. Juenke 4 , C. E. K. Chung 1 ; 1 Purdue Univ. Coll. of Pharmacy, Indianapolis, IN, 2 St. Francis Hosp., Indianapolis, IN, 3 Methodist Dallas Med. Ctr., Dallas, TX, 4 ARUP, Salt Lake City, UT. A-018 Pharmacokinetics and Monte Carlo Simulations of Doripenem in Patients with Febrile Neutropenia G. E. Stein, G. Kulhanek, C. Smith, J. Kuti, D. Nicolau, A. Scharmen, C. Farnum, M. Tran, A. Kalra, D. Havlichek; Michigan State Univ., East Lansing, MI. A-019 PKPD Target Attainment of Doripenem in Pediatric Patients Using Monte-Carlo Simulation

Y. Matsuo, M. Tsuji, T. Ishibashi, T. Katsube, T. Wajima; Shionogi Co. Ltd., Osaka, Japan.

A-020 Comparative Pharmacokinetics PK of Doripenem DOR in Infected Patients Treated In- and Out-Side the Intensive Care Unit ICU A. A. Bhalodi 1 , R. A. Keel 1 , R. Quintiliani 2 , T. P. Lodise 3 , D. P. Nicolau 1 , J. L. Kuti 1 ; 1 Ctr. for Anti-Infect. Res. Dev., Harford Hosp., Hartford, CT, 2 CT Multispecialty Group, Hartford Hosp., Hartford, CT, 3 Albany Coll. of Pharmacy and Hlth. Sci., Albany, NY. A-021 Population Pharmacokinetics PopPK of Imipenem IMP in Intensive Care Unit ICU Patients with Ventilator-Associated Pneumonia VAP

C. Couffignal

1,2 , O. Pajot 3 , L. Massias 1 , L. Armand-lefevre 1 , A. Foucrier 1 , C. Laouénan 1,2 , M. Wolff 1,4 , F. Mentré 1,2 ; 1 AP-HP, Hop BICHAT, Paris, France, 2 Univ. Paris Diderot, Sorbonne Paris Cité and Inserm, UMR 738, Paris, France, 3 Hop V Dupouy, Argenteuil, France, 4 Univ. Paris Diderot, Sorbonne Paris Cité, EA 3964, Paris, France. A-022 In Vitro Pharmacodynamics IVPD of Human Simulated Exposures of AmpicillinSulbactam SAM, Doripenem DOR, or Tigecycline TGC Alone and in Combination against Multi- drug-Resistant MDR Acinetobacter baumanii ACB S. T. Housman, M. Hagihara, D. P. Nicolau, J. L. Kuti; Ctr. Anti-Infect. Res. Devel., Hartford Hosp., Hartford, CT. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 004A Poster Session Polymyxins and Aminoglycosides: Optimizing PKPD and Dosing Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: A-023 In Vitro Pharmacodynamics of Polymyxin B PMB and Tigecycline TGC Alone and in Combination against Multi- drug-Resistant MDR Acinetobacter baumannii ACB

M. Hagihara

1,2 , S. T. Housman 1 , D. P. Nicolau 1 , J. L. Kuti 1 ; 1 Ctr. Anti- Infect. Res. and Dev., Hartford Hosp., Hartford, CT, 2 Aichi Med. Univ., Aichi, Japan. A-024 Polymyxin B PB in Combination Combo with Doripenem D against Acinetobacter baumannii Ab Demonstrates High Synergy and Suppression of Resistance G. G. Rao 1 , N. S. Ly 1 , R. L. Soon 1 , M. D. San Roman 1 , P. A. Kelchlin 1 , P. N. Holden 1 , P. Bergen 2 , J. B. Bulitta 2,1 , A. Forrest 1 , R. L. Nation 2 , J. Li 2 , B. T. Tsuji 1 ; 1 SUNY, Buffalo, NY, 2 Monash Univ., Melbourne, Australia. A-025 Pulmonary Target Delivery of Polymyxin B for Enhanced Efficacy

J. He, K. Abdelraouf, K. R. Ledesma, D. S. L. Chow, V. H. Tam; Univ. of Houston, Houston, TX.

A-026 Clinical Pharmacokinetics of Intravenous Polymyxin B1 and B2

C. J. Kubin

1 , E. Broun 1 , K. M. Abildskov 1 , J. Horan 2 , T. A. Thomas 1 , M. T. Yin 1 , S. Cremers 1 ; 1 Columbia Univ. Med. Ctr., New York, NY, 2 Duke Univ., Durham, NC. A-027 Steady-State SS Pharmacokinetics PK of Polymyxin B PB in Critically Ill Patients A. M. Sandri 1,2 , C. B. Landersdorfer 3 , J. Jacob 4 , M. M. Boniatti 5 , M. G. Dalarosa 5 , D. R. Falci 5 , T. F. Behle 6 , J. Wang 4 , A. Forrest 7 , R. L. Nation 4 , A. P. Zavascki 1,6 , J. Li 4 ; 1 Univ. Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2 Hosp. Sao Lucas da PUCRS, Porto Alegre, Brazil, 3 Ctr. for Med. Use Safety, Monash Univ., Melbourne, Australia, 4 Monash Inst. of Pharma- ceutical Sci., Monash Univ., Melbourne, Australia, 5 Hosp. Nossa Senhora da Conceição, Porto Alegre, Brazil, 6 Hosp. de Clín. de Porto Alegre, Porto Alegre, Brazil, 7 Sch. of Pharmacy Pharmaceutical Sci., SUNY, Buffalo, NY. A-028 Pharmacokinetics and Renal Disposition of Polymyxin B K. Abdelraouf, J. He, K. R. Ledesma, M. Hu, V. H. Tam; Univ. of Houston, Houston, TX. A-029 Polymyxin B Dosing Adjustment in Renal Insufficiency

V. H. Tam, J. He, K. Abdelraouf, K. R. Ledesma, M. Hu; Univ. of Houston, Houston, TX.

A-030 Colistin, Tigecycline and Daptomycin Combinations Improves Bacterial Kill of Acinetobacter baumannii

P. Komp Lindgren

1 , H. Seifert 2 , O. Cars 1 ; 1 ARunit, Uppsala, Sweden, 2 IMMIH, Cologne, Germany. A-031 Synergistic Killing of Colistin COL Combination COM- BO Therapy against Multidrug-Resistant MDR Acinetobacter baumannii Ab in Mouse Lung and Thigh Infection Models H. J. Lee 1 , J. Wang 1 , C. Ku 1 , B. T. Tsuji 2 , A. Forrest 2 , J. B. Bulitta 1,2 , J. Li 1 , R. L. Nation 1 ; 1 Monash Univ., Melbourne, Australia, 2 Univ. at Buffalo, Buffalo, NY. A-032 Optimal Design OD of a Colistin Sparse Sampling Schedule for Individual PK-Parameter Estimation

A. N. Kristoffersson, J. Nyberg, L. E. Friberg; Uppsala Univ., Uppsala, Sweden.

A-033 Whole Body Physiologically-Based Pharmacokinetic Model of Colistin and Colistimethate Sodium CMS in Healthy Volunteers

S. Bouchene

1 , L. E. Friberg 1 , S. Björkman 1 , W. Couet 2 , M. O. Karlsson 1 ; 1 Uppsala Univ., Uppsala, Sweden, 2 Poitiers Univ., Poitiers, France. 40 SCIENTIFIC SESSIONS September 9-12 | A-034 Risk Factors for and Incidence of Nephrotoxicity Associated with Intravenous Colistin in the Modern Era: A Systematic Review H. Pulluru, K. S. Kaye, J. M. Pogue, D. Marchaim, K. Hayakawa; Detroit Med. Ctr., Wayne State Univ., Detroit, MI. A-035 Pharmacokinetics of Colistin Methanesulfonate and Colistin after Lung Transplantion in Cystic Fibrosis Patients N. Grégoire 1 , F. Périn-Dureau 2 , P. Gobin 3 , C. Cerf 4 , D. Grenet 2 , F. Parquin 2 , O. Mimoz 3 , W. Couet 1,5 ; 1 Univ. of Poitiers, Poitiers, France, 2 Hosp. Foch, Suresnes, France, 3 CHU Poitiers, Poitiers, France, 4 Hosp. Foch, Suresnes, France, 5 Inserm, Poitiers, France. A-036 Plasma Pharmacokinetics and Sputum Concentrations of Colistin After Nebulisation or Intravenous Administration of Colistin Methansulphonate CMS to Ambulatories Cystic Fibrosis Patients S. Marchand 1 , A. Henriet 2 , N. Grégoire 1 , P. Gobin 1 , P. Diot 2 , W. Couet 1,3 ; 1 Univ. of Poitiers, Poitiers, France, 2 CHU Tours, Tours, France, 3 Inserm, Poitiers, France. A-037 Plasma Pharmacokinetics and Epithelial Lining Fluid ELF Concentrations of Colistin after Nebulisation or Intravenous Administration of Colistin Methanesulfonate CMS in Critical Care Patients M. Boisson 1 , S. Marchand 2 , N. Grégoire 2 , P. Gobin 1 , O. Mimoz 1 , W. Couet 2,3 ; 1 CHU Poitiers, Poitiers, France, 2 Univ. of Poitiers, Poitiers, France, 3 Inserm, Poitiers, France. A-038 Penetration of Arbekacin Sulfate to the Lung Tissue Y. Funatsu, N. Hasegawa, H. Nahmgunn, H. Fujiwara, T. Asami, T. Betsuyaku, S. Iwata; Keio Univ., Shinjuku-Ku, Japan. A-039 Pharmacologic Assessment of Guidelines on Gentamicin Use in Infective Endocarditis G. Beraud, A. Elsendoorn, C. Landron, C. Plouzeau, G. Le Moal, C. Godet, C. Burucoa, F. Roblot; Univ. Hosp. of Poitiers, Poitiers, France. A-040 Plazomicin PLZ Compared with Cefepime, Ciprofloxacin, Meropenem, Piperacillin-Tazobactam and Aminoglycosides for the Empiric Treatment of Gram-Negative, including Multidrug- Resistant MDR, Pathogens Causing Infections in Hospitals

S. Zelenitsky